Affordable Access

deepdyve-link
Publisher Website

Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases

Authors
  • Xuan, Liang1
  • Sun, Bing1
  • Meng, Xiangying1
  • Liu, Chao1
  • Cong, Yang1
  • Wu, Shikai2
  • 1 The Fifth Medical Center, Chinese PLA General Hospital, China , (China)
  • 2 Peking University First Hospital, China , (China)
Type
Published Article
Journal
Cancer Biology & Therapy
Publisher
Landes Bioscience
Publication Date
Oct 29, 2020
Volume
21
Issue
11
Pages
990–993
Identifiers
DOI: 10.1080/15384047.2020.1831370
PMID: 33121320
PMCID: PMC7678920
Source
PubMed Central
Keywords
Disciplines
  • Bedside-to-Bench Report
License
Unknown

Abstract

Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by suboptimal management of side effects. Here, we report two cases of docetaxel-based chemotherapy regimens in patients who exhibited invasive ductal breast cancer and underwent two different clinical treatment approaches. A 58-year-old postmenopausal female received salvage treatment with 8 cycles of docetaxel (67 mg/m2), and a 74-year-old female received 1 cycle of docetaxel (100 mg/m2). The two patients exhibited considerable hearing loss two days later. Of note, both patients had no hearing loss symptoms prior to docetaxel. Thus, ototoxicity may be a side effect of docetaxel that should be considered during treatment.

Report this publication

Statistics

Seen <100 times